Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
A Phase I Clinical Trial of FWD1802 in Patients With ER+/HER2- BC.
Details : FWD1802 is a drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Breast Neoplasms.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
October 03, 2023
Lead Product(s) : FWD1509
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : WuXi Clinical
Deal Size : Inapplicable
Deal Type : Inapplicable
A Study of FWD1509 in Adults With Non-Small Cell Lung Cancer
Details : FWD1509 is a drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Carcinoma, Non-Small-Cell Lung.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
October 05, 2021
Lead Product(s) : FWD1509
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : WuXi Clinical
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Dimethyl Fumarate
Therapeutic Area : Dermatology
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Efficacy Study on Dimethyl Fumarate to Treat Moderate to Severe Plaque Psoriasis
Details : FP187 is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Psoriasis.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
March 21, 2013
Lead Product(s) : Dimethyl Fumarate
Therapeutic Area : Dermatology
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Dimethyl Fumarate
Therapeutic Area : Dermatology
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Pivotal Efficacy and Safety Registration Trial of FP187 in Moderate to Severe Plaque Psoriasis
Details : FP187 is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Psoriasis.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
October 28, 2010
Lead Product(s) : Dimethyl Fumarate
Therapeutic Area : Dermatology
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable